Cargando…

Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?

The incidence of colorectal cancer (CRC) has declined over time, though it remains a significant cause of morbidity and mortality in the U.S. It has the third highest incidence in incidence among all cancers and is the second leading cause of cancer death in both men and women. Screening reduces the...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Taranika Sarkar, Rauch, Jessica, Shaukat, Aasma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643301/
https://www.ncbi.nlm.nih.gov/pubmed/38021363
http://dx.doi.org/10.21037/tgh-23-20
_version_ 1785134326519693312
author Das, Taranika Sarkar
Rauch, Jessica
Shaukat, Aasma
author_facet Das, Taranika Sarkar
Rauch, Jessica
Shaukat, Aasma
author_sort Das, Taranika Sarkar
collection PubMed
description The incidence of colorectal cancer (CRC) has declined over time, though it remains a significant cause of morbidity and mortality in the U.S. It has the third highest incidence in incidence among all cancers and is the second leading cause of cancer death in both men and women. Screening reduces the incidence and mortality from CRC. There are several modalities for CRC screening, but the most common ones are a choice between a non-invasive stool-based test, such as fecal immunochemical testing (FIT) or an invasive endoscopic modality, such as colonoscopy. In the U.S. colonoscopy is the predominant CRC screening modality, with observational studies reporting large reductions in CRC incidence and mortality. Recently, a large randomized controlled trial (RCT) on effectiveness of colonoscopy reported smaller than expected reduction in CRC incidence and no reduction in CRC mortality with colonoscopy screening. Explanations of the lower than expected benefit include low uptake of colonoscopy, short follow-up for mortality endpoints and quality indicators (QIs) for some of the endoscopists participating in the screening colonoscopies. The findings of the study need to be taken in context with other literature on effectiveness of colonoscopy, with the overall message of reassuring patients of the benefits of screening, and colonoscopy. Here, we discuss the latest evidence on colonoscopy screening and it in the context of other screening modalities and the landscape.
format Online
Article
Text
id pubmed-10643301
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-106433012023-08-30 Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population? Das, Taranika Sarkar Rauch, Jessica Shaukat, Aasma Transl Gastroenterol Hepatol Review Article The incidence of colorectal cancer (CRC) has declined over time, though it remains a significant cause of morbidity and mortality in the U.S. It has the third highest incidence in incidence among all cancers and is the second leading cause of cancer death in both men and women. Screening reduces the incidence and mortality from CRC. There are several modalities for CRC screening, but the most common ones are a choice between a non-invasive stool-based test, such as fecal immunochemical testing (FIT) or an invasive endoscopic modality, such as colonoscopy. In the U.S. colonoscopy is the predominant CRC screening modality, with observational studies reporting large reductions in CRC incidence and mortality. Recently, a large randomized controlled trial (RCT) on effectiveness of colonoscopy reported smaller than expected reduction in CRC incidence and no reduction in CRC mortality with colonoscopy screening. Explanations of the lower than expected benefit include low uptake of colonoscopy, short follow-up for mortality endpoints and quality indicators (QIs) for some of the endoscopists participating in the screening colonoscopies. The findings of the study need to be taken in context with other literature on effectiveness of colonoscopy, with the overall message of reassuring patients of the benefits of screening, and colonoscopy. Here, we discuss the latest evidence on colonoscopy screening and it in the context of other screening modalities and the landscape. AME Publishing Company 2023-08-30 /pmc/articles/PMC10643301/ /pubmed/38021363 http://dx.doi.org/10.21037/tgh-23-20 Text en 2023 Translational Gastroenterology and Hepatology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Das, Taranika Sarkar
Rauch, Jessica
Shaukat, Aasma
Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?
title Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?
title_full Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?
title_fullStr Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?
title_full_unstemmed Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?
title_short Colorectal cancer screening—what does the recent NordICC trial mean for the U.S. population?
title_sort colorectal cancer screening—what does the recent nordicc trial mean for the u.s. population?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643301/
https://www.ncbi.nlm.nih.gov/pubmed/38021363
http://dx.doi.org/10.21037/tgh-23-20
work_keys_str_mv AT dastaranikasarkar colorectalcancerscreeningwhatdoestherecentnordicctrialmeanfortheuspopulation
AT rauchjessica colorectalcancerscreeningwhatdoestherecentnordicctrialmeanfortheuspopulation
AT shaukataasma colorectalcancerscreeningwhatdoestherecentnordicctrialmeanfortheuspopulation